Monoclonal antibodies for the treatment of severe asthma

Current Allergy and Asthma Reports

Volumn 11, Issue 3, 2011, Pages 253-260

  Clienti, Salvatore ^a   Morjaria, Jaymin B ^b   Basile, Elisa ^a   Polosa, Riccardo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Biologics; Monoclonal antibodies; Severe asthma

Indexed keywords

AMG 317; ANTIASTHMATIC AGENT; DACLIZUMAB; ETANERCEPT; GOLIMUMAB; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 5; KELIXIMAB; MASITINIB; MEPOLIZUMAB; OMALIZUMAB; PITRAKINRA; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ASTHMA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; HUMAN; INFECTION; INJECTION SITE REACTION; NAUSEA; NOSE CONGESTION; REVIEW; RHINOPHARYNGITIS; SOLID TUMOR; T LYMPHOCYTE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRUS MENINGITIS;

ANTIBODIES, MONOCLONAL; ASTHMA; HUMANS; IMMUNOTHERAPY; SEVERITY OF ILLNESS INDEX;

EID: 79955898632     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-011-0184-9     Document Type: Review

References (73)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495-7.
2. Milstein C. With the benefit of hindsight. Immunol Today. 2000;21(8):359-64. (Pubitemid 30612295)
3. Hudson PJ, Souriau C. Engineered antibodies. Nat Med. 2003;9 (1):129-34. (Pubitemid 36098274)
4. Smith SL. Ten years of Orthoclone OKT3 (Muromonab-CD3): a review. J Transpl Coord. 1996;6(3):109-19. (Pubitemid 26386137)
5. Scott SD. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract. 1998;6(3):195-7. (Pubitemid 28225643)
6. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm080591.htm.
7. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplicaticons/ TherapeuticBiologicApplications/ucm093373.htm.
8. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet. 2006;368(9537):780-93. (Pubitemid 44279056)
9. BTS/SIGN (British Thoracic Society/Scottish Intercollegiate Network). British guideline on the management of asthma: a national clinical guideline. Thorax. 2008;63(Suppl IV):iv1-iv121.
10. Polosa R. An overview of chronic severe asthma. Intern Med J. 2008;38(3):190-8. (Pubitemid 351271404)
11. Smith DH, Malone DC, Lawson KA, Okamoto LJ, Battista C, Saunders WB. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med. 1997;156(3 Pt 1):787-93. (Pubitemid 27396416)
12. Antoncelli L, Bucca C, Neri M, De Benedetto F, Saabbatani PBF. Asthma severityand medical resource utilzation. Eur Respir J. 2004;23:723-9. (Pubitemid 38618143)
13. Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J. 2002;19(1):61-7. (Pubitemid 34105569)
14. Chanez P, Wenzel SE, Anderson GP, et al. Severe asthma in adults: what are the important questions? J Allergy Clin Immunol. 2007;119(6):1337-48.
15. Currie GP, Douglas JG, Heaney LG. Difficult to treat asthma in adults. BMJ. 2009;338:b494.
16. Polosa R, Benfatto GT. Managing patients with chronic severe asthma: rise to the challenge. Eur J Intern Med. 2009;20(2):114-24.
17. Morjaria JB, Polosa R. Recommendation for optimal management of severe refractory asthma. J Asthma Allergy. 2010;3:43-56.
18. Scheinberg DA, Chapman PB. Therapeutic applications of monoclonal antibodies for human disease. In: Birch JR, Lennox ES, editors. Monoclonal antibodies, principles and practice. New York: Wiley-Liss; 1995. p. 45-105.
19. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8(3):205-17. (Pubitemid 351323292)
20. Corne J, Djukanovic R, Thomas L, et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin Invest. 1997;99(5):879-87. (Pubitemid 27123624)
21. Presta L, Shields R, O'Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem. 1994;269(42):26368-73. (Pubitemid 24328457)
22. Shields RL, Whether WR, Zioncheck K, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol. 1995;107(1-3):308- 12.
23. Polosa R, Holgate ST. Omalizumab and severe allergic asthma. Oxford: Clinical Publishing; 2009. 52 pp.
24. Walker S, Monteil M, Phelan K, Lasserson TJ,Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006;2:CD003559.
25. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/ucm126456.htm.
26. Morjaria JB, Polosa R. Off-label use of omalizumab in nonasthma conditions: new opportunities. Expert Rev Respir Med. 2009;3(3):299-308.
27. Ohta K, Miyamoto T, Amagasaki T, Yamamoto M. Efficacy and safety of omalizumab in an Asian population with moderate-tosevere persistent asthma. Respirology. 2009;14(8):1156-65.
28. Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210-6. This was a clinical trial demonstrating the efficacy of omalizumab in children with moderate to severe uncontrolled atopic asthma.
29. Massanari M, Milgrom H, Pollard S, et al. Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate-severe allergic asthma. Clin Pediatr (Phila). 2009;48(8):859-65.
30. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol. 2007;63 (5):548-61. (Pubitemid 46632569)
31. Meno-Tetang GM, Lowe PJ. On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic Clin Pharmacol Toxicol. 2005;96(3):182-92. (Pubitemid 40387994)
32. Slavin RG, Ferioli C, Tannenbaum SJ,Martin C, Blogg M, Lowe PJ. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol. 2009;123(1):107-13. e3.
33. Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol. 2009;68(1):61-76.
34. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (updated 2009); Available at: http://www.ginasthma. org.
35. Domingo C, Moreno A, Jose Amengual M, Monton C, Suarez D, Pomares X. Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients. Curr Med Res Opin. 2011;27(1):45-53.
36. Russo C, Polosa R. TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. Clin Sci (Lond). 2005;109(2):135-42. (Pubitemid 41117296)
37. Morjaria JB, Malerba M, Polosa R. Biologic and pharmacologic therapies in clinical development for the inflammatory response in COPD. Drug Discov Today. 2010;15(9-10):396-405.
38. Cazzola M, Polosa R. Anti-TNF-alpha and Th1 cytokine-directed therapies for the treatment of asthma. Curr Opin Allergy Clin Immunol. 2006;6(1):43-50. (Pubitemid 44517808)
39. Howarth PH, Babu KS, Arshad HS, Lau LC, Buckley MG, McConnell W, et al. Tumour Necrosis Factor (TNF{alpha}) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma. Thorax. 2005;60:1012-8. (Pubitemid 41705469)
40. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006;354(7):697-708. (Pubitemid 43247140)
41. Morjaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, Holgate ST. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised placebo-controlled trial. Thorax. 2008;63:584-91. This was a DBPC study showing the lack of objective parameter improvements with etanercept use.
42. Holgate ST, Noonan M, Chanez P, et al. Efficacy/safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J. 2010 Nov 25 (Epub ahead of print). This was a large DBPC study reporting no improvements on any parameters of asthma assessment with use of etanercept. However, it also reported no safety concerns.
43. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factoralpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009;179(7):549-58. This was a large DBPC study showing not only no clinical improvements in individuals treated with golimumab but also high numbers of serious adverse events.
44. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol. 2006;24:147-74.
45. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood. 1992;79(12):3101-9.
46. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176 (11):1062-71. (Pubitemid 350223751)
47. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167(2):199-204. (Pubitemid 36076080)
48. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper- responsiveness, and the late asthmatic response. Lancet. 2000;356 (9248):2144-8.
49. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973-84. This was a small but relevant study demonstrating the efficacy and safety of mepolizumab in oral corticosteroid-dependent, sputum eosinophilic asthmatics.
50. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360(10):985-93. This was an important study reporting that mepolizumab reduces asthma exacerbations and improves quality of life in refractory eosinophilic asthma.
51. Polosa R, Morjaria J. Immunomodulatory and biologic therapies for severe refractory asthma. Respir Med. 2008;102(11):1499-510.
52. http://clinicaltrials.gov/ct2/show/NCT01000506?term=mepolizu mab+AND+asthma&rank=1.
53. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol. 2008;8(3):218-30. (Pubitemid 351323290)
54. Kon OM, Sihra BS, Loh LC, et al. The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ Tcells in asthma. Eur Respir J. 2001;18(1):45-52. (Pubitemid 32717430)
55. Kon OM, Sihra BS, Compton CH, Leonard TB, Kay AB, Barnes NC. Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet. 1998;352(9134):1109-13. (Pubitemid 28448517)
56. Azzawi M, Johnston PW, Majumdar S, Kay AB, Jeffery PK. T lymphocytes and activated eosinophils in airway mucosa in fatal asthma and cystic fibrosis. Am Rev Respir Dis. 1992;145(6):1477-82.
57. Kon OM, Kay AB. Anti-T cell strategies in asthma. Inflamm Res. 1999;48(10):516-23. (Pubitemid 29495632)
58. Park CS, LeeSM, ChungSW, Uh S,KimHT, KimYH. Interleukin-2 and soluble interleukin-2 receptor in bronchoalveolar lavage fluid from patients with bronchial asthma. Chest. 1994;106(2):400-6.
59. Busse WW, Israel E, Nelson HS, et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med. 2008;178(10):1002-8.
60. Grunig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science. 1998;282 (5397):2261-3. (Pubitemid 29004075)
61. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science. 1998;282(5397):2258-61. (Pubitemid 29004074)
62. Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol. 2003;111(4):677-90. quiz 91.
63. Rolling C, Treton D, Pellegrini S, Galanaud P, Richard Y. IL4 and IL13 receptors share the gamma c chain and activate STAT6, STAT3 and STAT5 proteins in normal human B cells. FEBS Lett. 1996;393(1):53-6.
64. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007;370(9596):1422-31. (Pubitemid 47576168)
65. http://clinicaltrials.gov/ct2/show/NCT00801853?term= Aerovant+AND+asthma&rank=1.
66. Corren J, Busse W, Meltzer EO, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med. 2010;181(8):788-96. This was a large study reporting the safety of AMG 317. Although there was no significant differences in any of the end points measured, it was thought to be clinically efficacious in patients with maximal symptoms.
67. Krishnamoorthy N, Oriss TB, Paglia M, et al. Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma. Nat Med. 2008;14(5):565-73. (Pubitemid 351655220)
68. Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol. 2006;533(1-3):327-40. (Pubitemid 43340024)
69. Chung KF, Hew M, Score J, et al. Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity. Eur Respir J. 2006;27(1):230-2. (Pubitemid 43092685)
70. Ingram JL, Bonner JC. EGF and PDGF receptor tyrosine kinases as therapeutic targets for chronic lung diseases. Curr Mol Med. 2006;6(4):409-21. (Pubitemid 43834254)
71. Hahn KA, Ogilvie G, Rusk T, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med. 2008;22(6):1301-9.
72. Humbert M, de Blay F, Garcia G, et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy. 2009;64(8):1194-201.
73. http://www.fp7-consulting.be/en/ubiopred/. 2008.